NEW YORK, March 21, 2016 /PRNewswire/ -- This BCC Research report provides an overview of the current state of the exosome industry, existing products on the market and detailed analysis of the competitive environments, including new potential markets for novel products, diagnostics and therapeutics development. Forecast provided for the period 2016-2021.
Use this report to:
Gain insight into the current state of the exosome industry and existing products on the market.
Analyze competitive environments, including new potential markets for novel products, diagnostics and therapeutics development.
Learn about significant players in the exosome industry, trends, obstacles, and other information effecting exosome market development.
Identify the main positive and negative factors within each sector.
The global market for exosome diagnostics and therapeutics is projected to grow from $16.1 million in 2016 to $111.8 million in 2021, a five-year compound annual growth rate (CAGR) of 47.3%.
Diagnostics is the largest sector of the market, expected to grow from $10.0 million in 2016 to $100.0 million in 2021 at a CAGR of 58.5% for the period.
Therapeutics is expected to grow from $5.0 million in 2016 to $10.0 million in 2021, a CAGR of 14.9%.
STUDY GOALS AND OBJECTIVES
This BCC Research report, Exosome Diagnostics and Therapeutics: Global Markets, provides an overview of the current state of the exosome industry, existing products on the market and detailed analysis of the competitive environments, including new potential markets for novel products, diagnostics and therapeutics development. The study includes information about significant players in this field of study, trends and obstacles and other information affecting exosome market development.
REASONS FOR DOING THIS STUDY
In the last decade, scientific research showed exponential growth in scientificpublication on exosomes, cell-derived vesicles.
By definition, exosomes are small membrane vesicles that are released by both healthy and cancerous cells. Substances from cell cytoplasm, such as genomic DNA (deoxyribonucleic acid), various RNA (ribonucleic acid) species, proteins and lipids are encapsulated into exosomes and are shed into the extracellular environment.
Importantly, research showed that all fluids in the human body contain exosomes, which can transfer cytoplasmic ingredients to other cells either locally or at distant sites. Once reaching the recipient cells, cytoplasmic ingredients can alter its biology.
Today, it is obvious that exosome research has enormous diagnostics and therapeutics potential. Since exosomes can be isolated from bodily fluids by ultracentrifugation and filtration, as well as by other approaches, they offer a very attractive alternative to invasive biopsy for the diagnosis and monitoring of cancer. The exosomes approach represents the opportunity to expand and develop new diagnostics tools in segments
such as liquid biopsy market, a growing sector in cancer diagnostics. Moreover, exosome research offers new alternatives for therapeutics development in general, especially in the sector of drug delivery platforms.
This report will highlight the main segments of the exosome industry and its major market participants, including current and future market trends. Drivers and challenges in each segment of this industry will be discussed in detail, including forecast for the next five years.
Read the full report: http://www.reportlinker.com/p03703402-summary/view-report.html
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/exosome-diagnostics-and-therapeutics-global-markets-300239196.html